AbbVie Inc.

BIT:1ABBV Stock Report

Market Cap: €352.0b

AbbVie Past Earnings Performance

Past criteria checks 0/6

AbbVie's earnings have been declining at an average annual rate of -9.6%, while the Biotechs industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 4.7% per year.

Key information

-9.58%

Earnings growth rate

-10.90%

EPS growth rate

Biotechs Industry Growth14.79%
Revenue growth rate4.65%
Return on equityn/a
Net Margin6.38%
Next Earnings Update31 Oct 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How AbbVie makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BIT:1ABBV Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2558,3283,72313,2158,568
31 Mar 2557,3674,15513,3468,385
31 Dec 2456,3344,23813,1898,131
30 Sep 2455,5335,08113,9247,755
30 Jun 2455,0005,29813,1937,405
31 Mar 2454,4035,95113,0327,189
31 Dec 2354,3184,82012,9047,038
30 Sep 2355,1386,47112,4536,897
30 Jun 2356,0238,63512,2606,785
31 Mar 2356,7417,53512,2016,661
31 Dec 2258,05411,78214,5846,487
30 Sep 2257,81913,34312,1166,518
30 Jun 2257,34912,56911,9886,551
31 Mar 2256,72512,40711,9436,692
31 Dec 2156,19711,46811,8726,820
30 Sep 2155,1697,46511,0546,829
30 Jun 2153,7296,59910,8606,761
31 Mar 2150,1955,09210,9556,418
31 Dec 2045,8044,5569,8676,003
30 Sep 2040,6507,3249,4295,902
30 Jun 2036,2276,9068,2885,582
31 Mar 2034,0578,3956,7605,467
31 Dec 1933,2667,8426,7635,377
30 Sep 1932,8673,2326,4875,260
30 Jun 1932,6244,0936,7655,273
31 Mar 1932,6475,3336,8735,304
31 Dec 1832,7535,6577,3535,259
30 Sep 1832,1877,5316,9725,242
30 Jun 1830,9466,4196,6235,202
31 Mar 1829,6126,3526,3035,109
31 Dec 1728,2165,2836,2485,007
30 Sep 1727,2736,6155,9584,789
30 Jun 1726,7106,5825,7994,667
31 Mar 1726,2186,2785,8614,562
31 Dec 1625,6385,9235,8374,385
30 Sep 1625,2426,0485,7334,178
30 Jun 1624,7545,6905,7244,472
31 Mar 1623,7775,4485,6464,236
31 Dec 1522,8595,1185,6634,101
30 Sep 1521,9112,7906,0593,978
30 Jun 1520,9862,0646,1783,390
31 Mar 1520,4371,8026,1333,336
31 Dec 1419,9601,7656,0243,297

Quality Earnings: 1ABBV has a large one-off loss of $14.5B impacting its last 12 months of financial results to 30th June, 2025.

Growing Profit Margin: 1ABBV's current net profit margins (6.4%) are lower than last year (9.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1ABBV's earnings have declined by 9.6% per year over the past 5 years.

Accelerating Growth: 1ABBV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1ABBV had negative earnings growth (-29.7%) over the past year, making it difficult to compare to the Biotechs industry average (85.9%).

Return on Equity

High ROE: 1ABBV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 23:51
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AbbVie Inc. is covered by 55 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Luisa HectorBerenberg
Evan SeigermanBMO Capital Markets Equity Research